Nisshin Pharma and Others to Co-develop Functional Foods for Alleviating and Preventing Gastric Lesions.
In this project, the two companies and the Keio University School of Medicine will strive to develop functional foods for alleviating and preventing upper gastrointestinal (GI) tract lesions caused by Helicobacter pylori.
The three partners will fully leverage their strengths, namely, Nisshin Pharma's capabilities to develop health foods, GHEN's expertise in chicken antibodies (IgY), and Keio University's knowledge about Helicobacter pylori and mucosal lesions of the upper GI tract.
The government subsidized project will continue for three years from July 2006.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||May 23, 2006|
|Previous Article:||LTT Bio-Pharma Announces Results of Research on Porous Hydroxyapatite Particles.|
|Next Article:||ITO EN Confirms that Boiled Carrots have Higher Absorption Rates of Beta-Carotene.|